Review record · October 16, 2026
Line-by-line content review
Six activities reviewed. Written corrections and all nine identified narration copy edits are applied; pronunciation approval remains open.
This is an editorial, evidence-source and consistency review. It is not independent clinical or accredited-provider release approval.
Corrections applied
HFpEF written lesson
Added a separate readable version of all 154 teaching paragraphs, with standard clinical abbreviations and corrected grammar. The nine identified narration copy edits have now been recorded; their scripts, captions and full HFpEF teaching videos are synchronized.
HFpEF questions
Added missing laboratory units in nine assessment items or their feedback; synchronized the active course, import CSVs, answer key and complete workbook. Correct-answer keys are unchanged.
Kidney lesson
Replaced an author-facing instruction with a direct learner prompt in the lesson, reading guide and source copies.
Obesity/diabetes lesson
Clarified the nutrition question about usual intake and avoided foods in the written lesson, host source and manuscript.
Six budgets
Removed duplicated payee wording, rechecked every quantity × rate, total and educator-fee percentage, and refreshed matching budget PDFs. All six educator shares remain below 20%.
HFpEF fee boundary
Clarified that funding must exceed $137,500 for a $27,500 fee to remain below 20% of the funded total.
HFpEF host and certificate instructions
Replaced superseded 4-of-6 instructions with the active three-module requirements and accurate HTML/JSON learning-record behavior. Marked the foundation source as superseded and included the current policy and certificate notes in the handoff.
Download and PDF presentation
Rebuilt all six host packages. Kept complete questions together in the HFpEF staff key and removed nearly empty spillover pages from the upload guide and budgets.
Verification
- Correct-answer keys preserved across all six canonical sources.
- 32 of 32 caption/transcript pairs match after excluding titles, chapter headings and cue numbers.
- All six budget totals and educator-fee percentages reconcile.
- Learner-flow, first-attempt retention, completion-record and real-package download checks pass.
- Affected PDFs were text-checked and visually sampled; this is not a browser/device accessibility audit.
Additional close-reading corrections
- Restored all 11 obesity clinical setups and the choices for its six required decisions; clarified its five worked examples.
- Added the HF module 2 required dosing note before assessment and four primary references.
- Moved the kidney framework citation out of the objectives and restored the evidence table.
- Added the required hyperkalemia recording clarification and balanced label cautions.
- Linked the needs evidence in each grant narrative and corrected current guide/navigation references.
- Corrected six MP3 artist tags to RPA-C; decoded narration is unchanged. Rechecked the nine major audio/video endings and five flagged regions.
The nine narration copy edits below are applied; the listening flags remain open. New written notes are not claimed to be spoken in existing recordings.
Nine narration copy edits applied
These nine passages have been replaced using Lisa’s authorized saved voice. Captions and transcripts match the revised recordings. The remaining listening checks are the five time-stamped pronunciation flags.
1. Obesity Diabetes
Previous script: Ask what she usually eats and what she fears restricting. Build the plan around familiar, affordable foods.
Applied wording: Ask what she usually eats, which foods she avoids and why. Build the plan around familiar, affordable foods.
2. Obesity Diabetes
Previous script: Elena takes metformin and secondary-prevention medicines after an myocardial infarction three years ago. She is postmenopausal and has no acute symptoms. A colleague proposes waiting for A one C to rise before reviewing additional diabetes therapy.
Applied wording: Elena takes metformin and secondary-prevention medicines after a myocardial infarction three years ago. She is postmenopausal and has no acute symptoms. A colleague proposes waiting for A one C to rise before reviewing additional diabetes therapy.
3. Hfpef In Women
Previous script: Separate a pooled analysis from an heart failure with preserved ejection fraction trial.
Applied wording: Separate a pooled analysis from a heart failure with preserved ejection fraction trial.
4. Hfpef In Women
Previous script: FINE-HEART pooled participant-level data from FIDELIO D K D, FIGARO D K D and FINEARTS H F. Its 18,991 participants span chronic kidney disease with type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction. It is not a new head-to-head trial and is not an heart failure with preserved ejection fraction-only population. Its primary cardiovascular-death result did not reach statistical significance (hazard ratio 0.89, 95 percent confidence interval 0.78 to 1.01).
Applied wording: FINE-HEART pooled participant-level data from FIDELIO D K D, FIGARO D K D and FINEARTS H F. Its 18,991 participants span chronic kidney disease with type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction. It is not a new head-to-head trial and is not a heart failure with preserved ejection fraction-only population. Its primary cardiovascular-death result did not reach statistical significance (hazard ratio 0.89, 95 percent confidence interval 0.78 to 1.01).
5. Hfpef In Women
Previous script: Current task. Reconcile therapy and assess eligibility and safety before adding an mineralocorticoid receptor antagonist.
Applied wording: Current task. Reconcile therapy and assess eligibility and safety before adding a mineralocorticoid receptor antagonist.
6. Pregnancy Heart History
Previous script: Maria is 46 and attends a preventive visit. She has no known atherosclerotic cardiovascular disease or diabetes and no current symptoms. L D L cholesterol is 158 milligrams per deciliter, H D L cholesterol 49 milligrams per deciliter and triglycerides 145 milligrams per deciliter. She reports treated hypertension and a father who had an myocardial infarction at 49. She does not smoke. When asked directly, she describes severe preeclampsia with a delivery at 31 weeks. Her chart does not contain this history. She is not pregnant or breastfeeding and has no current pregnancy plans.
Applied wording: Maria is 46 and attends a preventive visit. She has no known atherosclerotic cardiovascular disease or diabetes and no current symptoms. L D L cholesterol is 158 milligrams per deciliter, H D L cholesterol 49 milligrams per deciliter and triglycerides 145 milligrams per deciliter. She reports treated hypertension and a father who had a myocardial infarction at 49. She does not smoke. When asked directly, she describes severe preeclampsia with a delivery at 31 weeks. Her chart does not contain this history. She is not pregnant or breastfeeding and has no current pregnancy plans.
7. Pregnancy Heart History
Previous script: Elena is 58, has type 2 diabetes, and had an myocardial infarction two years ago. She is postmenopausal. L D L cholesterol is 92 milligrams per deciliter while prescribed a high-intensity statin. She also reports preeclampsia many years earlier. The current decision is secondary prevention for established atherosclerotic cardiovascular disease. Her pregnancy history remains part of her record, but it does not replace the evidence-based treatment pathway for her myocardial infarction and diabetes.
Applied wording: Elena is 58, has type 2 diabetes, and had a myocardial infarction two years ago. She is postmenopausal. L D L cholesterol is 92 milligrams per deciliter while prescribed a high-intensity statin. She also reports preeclampsia many years earlier. The current decision is secondary prevention for established atherosclerotic cardiovascular disease. Her pregnancy history remains part of her record, but it does not replace the evidence-based treatment pathway for her myocardial infarction and diabetes.
8. Hyperkalemia Heart Kidney
Previous script: Sofia is not being asked to start an mineralocorticoid receptor antagonist while the current potassium problem is unresolved. The distinction matters because “preserve treatment” can otherwise become an overly broad instruction to intensify every cardioprotective medicine at once.
Applied wording: Sofia is not being asked to start a mineralocorticoid receptor antagonist while the current potassium problem is unresolved. The distinction matters because “preserve treatment” can otherwise become an overly broad instruction to intensify every cardioprotective medicine at once.
9. Hyperkalemia Heart Kidney
Previous script: Third ask what changed. Potassium concentration, recurrence of hyperkalemia, persistence on an mineralocorticoid receptor antagonist and a clinical event are distinct outcomes. Do not convert success on one into an unstated claim about another. If Margaret asks about longevity, answer that question directly and then explain the more limited outcome the trial supports.
Applied wording: Third ask what changed. Potassium concentration, recurrence of hyperkalemia, persistence on a mineralocorticoid receptor antagonist and a clinical event are distinct outcomes. Do not convert success on one into an unstated claim about another. If Margaret asks about longevity, answer that question directly and then explain the more limited outcome the trial supports.
Selected current sources rechecked
- ADA 2026: postpartum testing
- Foundayo prescribing information
- Wegovy prescribing information
- Zepbound prescribing information
- Kerendia prescribing information
- 2026 ESC heart-failure guideline summary
- SURPASS-CVOT publication
- ACHIEVE-4 publication
- Lp(a)HORIZON sponsor topline release
- UK Kidney Association hyperkalemia guideline
- Lokelma prescribing information
- Veltassa prescribing information
Remaining release work
Full human listening and narration approval, independent clinical and assessment approval, a timed learner pilot, real-device and assistive-technology testing, native host acceptance, and provider release approval remain pending. No CME/CE credit has been designated.